Related Experiment Videos
Glucocorticoids decrease interleukin-6 levels and induce mineralization of cultured osteogenic cells from children
R P Stanton1, G M Hobson, B E Montgomery
1Department of Orthopaedics, Alfred I. duPont Hospital for Children, Wilmington, Delaware 19803, USA.
Summary
Fibrous dysplasia (FD) is a bone disorder caused by GNAS gene mutations. Glucocorticoids show promise in treating FD by normalizing osteogenic stem cells and reducing inflammatory markers.
Area of Science:
- Bone biology
- Genetics
- Cellular and molecular medicine
Background:
- Fibrous dysplasia (FD) is a progressive bone disease characterized by abnormal fibroblast proliferation and replacement of normal bone with immature fibrous tissue.
- FD presents as monostotic (single bone) or polyostotic (multiple bones) forms, with McCune-Albright syndrome being a severe variant involving endocrinopathies.
- Somatic activating mutations in the GNAS gene are implicated in FD, leading to increased cAMP, elevated interleukin-6 (IL-6), abnormal osteoblast differentiation, and increased osteoclast activity.
Purpose of the Study:
- To investigate the potential of culturing osteogenic stem cells from FD patients.
- To explore the role of GNAS gene mutations in different forms of FD.
- To assess the therapeutic potential of glucocorticoids in modulating cellular function and IL-6 levels in FD.
Main Methods:
- Culturing osteogenic stem cells from the affected stroma of 11 FD patients using established mammalian bone marrow stromal cell techniques.
- Analyzing the frequency of Gsalpha mutations in cells from polyostotic versus monostotic FD patients.
- Treating cultured cells with glucocorticoids to evaluate changes in osteogenic phenotype, IL-6 mRNA, and protein levels.
Main Results:
- Osteogenic stem cells were successfully cultured from FD patient stroma.
- Cells from polyostotic FD patients exhibited a higher frequency of the Gsalpha mutation compared to monostotic FD patients.
- Glucocorticoid treatment induced an osteogenic phenotype in both normal and FD cells and significantly inhibited IL-6 production in FD cells.
Conclusions:
- Cultured osteogenic stem cells from FD patients provide a model for studying the disease.
- Glucocorticoids demonstrate potential as a therapeutic agent for FD by modulating cellular behavior and reducing key inflammatory mediators.
- These findings suggest that targeting cellular function with chemical alterations may offer new treatment avenues for fibrous dysplasia.